Use of niacin, statins, and resins in patients with combined hyperlipidemia

American Journal of Cardiology

Volumn 81, Issue 4 A, 1998, Pages 52B-59B

  Brown, B Greg ^a   Zambon, Alberto ^a   Poulin, Drew ^a   Rocha, Anita ^a   Maher, Vincent M G ^a   Davis, Joseph W ^a   Albers, John J ^a   Brunzell, John D ^a  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN B; COLESTIPOL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN; MEVINOLIN; NICOTINIC ACID; PLACEBO; RESIN; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CORONARY ARTERY OBSTRUCTION; CORONARY RISK; DRUG EFFICACY; DRUG RESPONSE; HUMAN; HYPERLIPIDEMIA; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; TREATMENT OUTCOME; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 0032568085     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9149(98)00039-3     Document Type: Conference Paper

References (20)

1. Goldstein JL, Schroff HG, Hazzard WR, Bierman EL, Motulsky AG. Hyperlipidemia in coronary artery disease, II: genetic analysis of lipid levels in 176 families and delineation of a new inherited disorder, combined hyperlipidemia. J Clin Invest 1973;52:1544-1568.
2. Utermann G, Jaeschike M, Menzel J. Familial hyperlipoproteinemia, type II: deficiency of a single apolipoprotein (apo E-III) in the very low density lipoproteins. FEBS Lett 1975;56:352-355.
3. Grundy SM. Small LDL, atherogenic dyslipidemia and the metabolic syndrome. Circulation 1997;95:1-4.
4. Reaven GM, Chen YD, Jeppesen J, Maheux P, Krauss RM. Insulin resistance and hyperinsulinemia in individuals with small, dense LDL particles. J Clin Invest 1993;92:141-146.
5. Babirak SP, Brown BG, Brunzell JD. Familial combined hyperlipidemia and abnormal lipoprotein lipase. Arterioscler Thromb 1992;12:1176-1183.
6. Gardner CD, Fortman SP, Krauss RM. Association of small low-density-lipoprotein particles with incidence of coronary artery disease in men and women. JAMA 1996;276:875-881.
7. Zambon A, Austin MA, Brown BG, Hokanson JE, Brunzell JD. Effects of hepatic lipase on LDL in normal men and those with coronary artery disease. Arterioscler Thromb 1993;13:147-153.
8. Assmann G, Schulte H. Relation of high-density lipoprotein cholesterol and triglyceride to incidence of atherosclerotic coronary artery disease (the PROCAM experience). Am J Cardiol 1992;70:733-737.
9. Stampfer MJ, Krauss RM, Ma J, Blanche PJ, Holl LG, Sacks FM, Hennekens CH. A prospective study of triglyceride level, low-density lipoprotein particle diameter, and risk of myocardial infarction. JAMA 1996;276:882-888.
10. Manninen V, Tenkanen L, Koskinen P, Manttari M, Heinomen OP, Frick H. Joint effects of serum triglyceride and LDL cholesterol and HDL cholesterol concentrations on coronary artery disease risk in the Helsinki Heart Study: implications for treatment. Circulation 1992;85:37-45.
11. Stewart BF, Brown BG, Zhao X-Q, Hillger LA, Sniderman AD, Dowdy A, Fisher LD, Albers JJ. Benefits of lipid-lowering therapy in men with elevated apolipoprotein B are not confined to those with very high LDL cholesterol. J Am Coll Cardiol 1994;23:899-906.
12. Miller BM, Alderman EL, Haskell WL, Fair JM, Krauss RM. Predominance of dense low-density lipoprotein particles predicts angiographic benefit of therapy in Stanford Coronary Risk Intervention Project. Circulation 1996; 94:2146-2153.
13. Mack WJ, Krauss RM, Hodis HN. Lipoprotein subclasses in the Monitored Atherosclerosis Regression Study (MARS): treatment effects and relation to coronary angiographic progression. Arterioscler Thromb Vasc Biol 1996;16:697-704.
14. Phillips NR, Waters D, Havel RJ. Plasma lipoproteins and progression of coronary artery disease elevated by angiography and clinical events. Circulation 1993;88:2762-2770.
15. Alaupovic P, Mack WJ, Knight-Gibson C, Hodis HN. The role of triglyceride-rich lipoprotein families in the progression of atherosclerotic lesions as determined by sequential coronary angiography from a controlled clinical trial. Arterioscler Thromb Vasc Biol 1997;17:715-722.
16. Krauss RM, Burke DJ. Identification of multiple subclasses of plasma low density lipoproteins in normal humans. J Lipid Res 1982;23:97-104.
17. Brown BG, Albers JJ, Fisher LD, Schaefer SM, Lin J-T, Kaplan C, Zhao X-Q, Bisson BD, Fitzpatrick VF, Dodge HT. Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. N Engl J Med 1990;323:1289-1298.
18. Auwerx JH, Marzetta CA, Hokanson JE, Brunzell JD. Large, buoyant LDL-like particles in hepatic lipase deficiency. Arteriosclerosis 1989;9:319-325.
19. Brown BG, Hillger LA, Lewis C, Zhao X-Q, Socco D, Bisson B, Fisher L. A maximum confidence approach for measuring progression and regression of coronary artery disease in clinical trials. Circulation 1993;87(suppl II):66-73.
20. Zambon A, Brown BG, Hokanson JE, Brunzell JD. Hepatic lipase changes predict coronary artery disease progression/regression in the Familial Atherosclerosis Treatment Study (FATS). (Abstr). Circulation 1996;94(suppl I):I-539.